Eli Lilly & Co. has been hit with another lawsuit over it schizophrenia drug, Zyprexa, adding to the pharmaceutical company’s legal woes over one of its top-selling drugs.
In a surprise turnaround, a Pennsylvania state court judge has declared a mistrial in the first state court trial over Wyeth’s hormone replacement therapy drug, overturning a jury’s finding that Prempro was a cause of a woman's breast cancer.
Congress should better regulate and should give more money to the U.S. Food and Drug Administration so it can make drugs safer for consumers, according to a report published Monday.
A federal appeals court reinstated a case Thursday brought by several Michigan residents who say they were hurt from taking the diabetes drug, Rezulin, which was yanked from the market in 2000.
After six days of deliberations, jurors in the first state court trial over Wyeth’s hormone replacement therapy drugs finally reached a decision on Wednesday, finding that Prempro was a cause of a woman's breast cancer and ordering the drug maker to shell out $1 million in compensatory damages.
An association of doctors who implant defibrillators and pacemakers has recommended that the U.S. Food and Drug Administration enhance existing post-market surveillance databases and better communicate with the public about device malfunctions.
Jurors in the first state court trial over claims that Wyeth’s hormone replacement therapy drugs increase the risk of heart disease, stroke and cancer remained deadlocked on Thursday, with the judge ordering them back to court on Friday to attempt to reach a verdict.
Merck & Co. said late Tuesday that a jury had cleared the company of responsibility for a Kentucky man's heart attack, marking the company’s second federal win in the slew of litigation it faces over its painkiller Vioxx.
Europe’s top drug agency has launched another review of commonly used anti-inflammatory drugs amid concerns over a link to heightened risk of heart attacks.
Pharmaceutical giant Merck & Co. may be plunged into even deeper hot water in the next few days over its painkiller Vioxx, as plaintiffs attorneys rush to file additional lawsuits ahead of a September 30 deadline.
The Food & Drug Administration has ordered a first round of studies to address the safety of medicines already on the market. Attention deficit hyperactivity disorder, osteoporosis and contraceptive medications will be the first to face scrutiny.
Natural foods company AMS Health Sciences Inc. settled a contentious wrongful-death claim Wednesday stemming from its past sales of ephedra-based products. The lawsuit was the last in a series of claims against AMS over the now-banned herbal product.
Four litigation partners with Mayer Brown Rowe & Maw LLP have jumped ship, leaving the firm’s New York office to join rival firm Morrison Foerster LLP.
Drug giant Wyeth walked away from its first courtroom battle over Premarin and Prempro with a victory on Friday. The decision may signal how the pharmaceutical company will proceed with the approximately 5,000 lawsuits it still faces over the hormone replacement therapy drugs.
Two former executives who sold millions of dollars in faulty sterilization devices that have been blamed for leaving 18 patients blind in one eye have been sentenced to prison time.
The U.S. Food and Drug Administration is concerned about recent study results of the long-term effects of drug-coated stents and will soon look into data at both Boston Scientific Corp. and rival Johnson & Johnson, according to a statement from the agency.
Putting to rest one of thousands of lawsuits it faces over implantable heart defibrillators, Boston Scientific Corp. has settled a fraud action over one of the recalled devices manufactured by its Guidant Corp. division.
The same U.S. Food and Drug Administrator that railed against the agency’s actions during the rise and fall of Merck & Co. Inc.’s blockbuster arthritis drug Vioxx made headlines again on Wednesday when he criticized the drug company’s experimental painkiller, Arcoxia, saying it may carry the same risk of heart attacks and strokes as Vioxx.
Biopure Corp. won’t have to pay a cent to the Securities and Exchange Commission to settle allegations of issuing false and misleading public statements, though its general counsel wasn’t as lucky.
Wrapping up three weeks of testimony, jury deliberations began on Tuesday in the first trial over claims that Wyeth’s hormone replacement therapy drugs, which were used to treat the symptoms of menopause, increase the risk of heart disease, stroke and cancer.